These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38095707)

  • 81. Common practices in botulinum toxin injection for spasmodic dysphonia treatment: A national survey.
    Shoffel-Havakuk H; Rosow DE; Lava CX; Hapner ER; Johns MM
    Laryngoscope; 2019 Jul; 129(7):1650-1656. PubMed ID: 30582627
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Spasmodic Dysphonia].
    Tokashiki R
    Brain Nerve; 2023 Jan; 75(1):15-22. PubMed ID: 36574969
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Botulinum toxin type A therapy for cervical dystonia.
    Rodrigues FB; Duarte GS; Marques RE; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD003633. PubMed ID: 33180963
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Vibratory Onset of Adductor Spasmodic Dysphonia and Muscle Tension Dysphonia: A High-Speed Video Study✰.
    Chen W; Woo P; Murry T
    J Voice; 2020 Jul; 34(4):598-603. PubMed ID: 30595236
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Management of supraglottic squeeze in adductor spasmodic dysphonia: a new technique.
    Young N; Blitzer A
    Laryngoscope; 2007 Nov; 117(11):2082-4. PubMed ID: 17828055
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Spasmodic dysphonia follow-up with videolaryngoscopy and voice spectrography during treatment with botulinum toxin.
    Esposito M; Dubbioso R; Apisa P; Allocca R; Santoro L; Cesari U
    Neurol Sci; 2015 Sep; 36(9):1679-82. PubMed ID: 25966878
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Vocal outcome measures after bilateral posterior cricoarytenoid muscle botulinum toxin injections for abductor spasmodic dysphonia.
    Klein AM; Stong BC; Wise J; DelGaudio JM; Hapner ER; Johns MM
    Otolaryngol Head Neck Surg; 2008 Sep; 139(3):421-3. PubMed ID: 18722224
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: a review of 22 studies.
    Whurr R; Nye C; Lorch M
    Int J Lang Commun Disord; 1998; 33 Suppl():327-9. PubMed ID: 10343714
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Prospective study of patients' subjective responses to botulinum toxin injection for spasmodic dysphonia.
    Liu TC; Irish JC; Adams SG; Durkin LC; Hunt EJ
    J Otolaryngol; 1996 Apr; 25(2):66-74. PubMed ID: 8683655
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Botulinum toxin therapy for abductor spasmodic dysphonia.
    Woodson G; Hochstetler H; Murry T
    J Voice; 2006 Mar; 20(1):137-43. PubMed ID: 16126369
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
    Morzaria S; Damrose EJ
    J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
    Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
    J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Simultaneous Botox and Augmentation Injection Laryngoplasty in Patients With Adductor Spasmodic Dysphonia (ASD) and Tremor.
    Woo P
    J Voice; 2022 Aug; ():. PubMed ID: 36050248
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Impact of an Upper Respiratory Tract Infection on Botulinum Toxin Efficacy in Spasmodic Dysphonia Patients.
    Kirke DN; Kaye R; Blitzer A
    Laryngoscope; 2020 Jul; 130(7):1746-1749. PubMed ID: 31508822
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia.
    Bielamowicz S; Ludlow CL
    Ann Otol Rhinol Laryngol; 2000 Feb; 109(2):194-203. PubMed ID: 10685573
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The safety and efficacy of botulinum toxin for management of scars: A systematic review with meta-analysis and trial sequential analysis.
    Wang D; Qu J; Jiang H; Jiang Y
    Toxicon; 2019 Aug; 166():24-33. PubMed ID: 31047933
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Botox treatment in adductor spasmodic dysphonia: a meta-analysis.
    Boutsen F; Cannito MP; Taylor M; Bender B
    J Speech Lang Hear Res; 2002 Jun; 45(3):469-81. PubMed ID: 12069000
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia.
    Ludlow CL; Naunton RF; Sedory SE; Schulz GM; Hallett M
    Neurology; 1988 Aug; 38(8):1220-5. PubMed ID: 3399071
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Adductor spasmodic dysphonia and botulinum toxin treatment: the effect on well-being.
    Langeveld TP; Luteijn F; van Rossum M; Drost HA; Baatenburg de Jong RJ
    Ann Otol Rhinol Laryngol; 2001 Oct; 110(10):941-5. PubMed ID: 11642427
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Significance of age and sex in botulinum neurotoxin dosing for adductor spasmodic dysphonia.
    Heyes R; Adler CH; Zhang N; Lott DG; Bansberg SF
    World J Otorhinolaryngol Head Neck Surg; 2023 Jun; 9(2):168-173. PubMed ID: 37383332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.